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Atrial fibrillation (AF) is the most common cardiac arrhyth-mia and is a major risk factor for ischemic stroke,1,2 par-
ticularly among elderly patients.3 Stroke is the most feared 
complication in patients with AF because AF is associated 
with a higher risk of adverse outcome after stroke.4,5
Several clinical trials have documented the efficacy of oral 
anticoagulation treatment (OAT) for prevention of cardioem-
bolic stroke in patients with AF.6 Less is known about the pos-
sible effect of preadmission OAT on stroke outcomes. Only 
a few observational studies have examined the association, 
and overall preadmission OAT has been found to be associ-
ated with less severe stroke, lower case fatality, and improved 
functional level.7–13 If this association is truly causal, it consti-
tutes a strong argument for increasing the efforts to ensure that 
eligible patients with AF receive OAT according to clinical 
guideline recommendations. This is important because several 
studies have found that high proportions of eligible patients 
with AF, including high-risk patients, are withheld OAT.14
However, several uncertainties related to limitations of 
the existing studies remain to be clarified before a more 
firm conclusion can be made. Most of the existing studies 
have not been population based, and none are nationwide, 
which raises concerns about the generalizability of the find-
ings. Furthermore, the ability to control adequately for pos-
sible confounding factors and the statistical precision could 
be questioned. Finally, all except for one small study11 have 
been restricted to patients with ischemic stroke although the 
possible beneficial effect of OAT on ischemic events could 
potentially be outweighed by a potential harm in patients 
with intracerebral hemorrhage (ICH). There is consequently 
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a need for additional large-scale population-based studies. 
Therefore, we examined the preadmission use of OAT among 
hospitalized Danish patients with stroke with AF and the 
association with stroke severity and case fatality in a nation-
wide, population-based follow-up study.
Methods
The study was based on national Danish registries covering the en-
tire population (≈5.5 million). The Danish National Health Service 
provides tax-financed healthcare to all residents, and unambiguous 
individual-level linkage between registries is enabled by a unique 
10-digit civil registration number that is assigned to every citizen and 
used in all registries.
Study Population
We identified all Danes (≥18 years) admitted with acute stroke (in-
cluding ischemic stroke and ICH) from January 2003 to December 
2009 (n=11 356; Figure). Patients with multiple strokes during the 
study period were only included with their first stroke. All the patients 
had a known history of AF or were diagnosed with AF on admission 
with the stroke.
The patients were identified in the Danish Stroke Registry. 
Participation in the project is mandatory for all hospital departments 
in Denmark treating patients with acute stroke.15 Almost all patients 
have brain computed tomography or MRI scans in the acute stroke 
phase (97% of the study population). The completeness of the regis-
tration of patients is estimated to be >90% when compared with the 
Danish National Registry of Patients.
OAT Use
Data on all OAT (warfarin and phenprocoumon) prescriptions filled 
before the date of admission with stroke were obtained on each patient 
by linkage with the Danish Medicines Agency’s Medical Registry. 
The register contains data from 1995 on all prescription drugs dis-
pensed at Danish pharmacies, including type of drug according to 
the Anatomic Therapeutic Chemical classification system and date 
of dispensing the drug. In Denmark, OATs are available by prescrip-
tion only. Patients who had filled a prescription within 90 days before 
admission, which is the conventional prescription length, were con-
sidered current users at the time of admission.
Outcomes
Stroke Severity
Stroke severity was assessed at the time of admission using the 
Scandinavian Stroke Scale score.16,17 Severity was classified as severe 
(0–29 points) versus nonsevere (≥30 points).
30-Day Mortality Rate
Mortality rate was assessed using information from the Danish Civil 
Registration System. The Danish Civil Registration System keeps 
daily updated electronic records on change of address, date of emi-
gration, and changes in vital status.18
Length of Hospital Stay
Length of stay was defined as the time span from admission to dis-
charge. The admission date was defined as the date the patient was 
admitted to the hospital with stroke or the date of stroke occurrence if 
the patient was already hospitalized with another diagnosis.
Patient Characteristics
We obtained information on a range of patient characteristics to iden-
tify patient-related predictors of the preadmission OAT use and to 
minimize the risk of confounding when comparing clinical outcome 
among patients with and without preadmission OAT use (Tables 1 
and 2). The data were obtained from the Danish Stroke Registry, 
the National Registry of Patients,19 the Danish Medicines Agency’s 
Medical Register, and the Integrated Database for Labour Market 
Research20 and include age, sex, comorbidity (specific comorbidities 
and Charlson comorbidity score),21 type of stroke, previous admis-
sions with AF, education, employment, income, preadmission use of 
other drugs (blood pressure–lowering drugs, lipid-lowering drugs, 
platelet inhibitors, and antidiabetic drugs), treatment with intravenous 
thrombolysis, body mass index, alcohol intake, smoking habits, qual-
ity of early stroke care, and calendar year.
Furthermore, we computed the preadmission CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mel-
litus, previous stroke/transient ischemic attack, vascular disease, 
age 65–74 years, sex category; age ≥75 years, and previous stroke 
carry doubled risk weight)22,23 and HAS-BLED (hypertension, ab-
normal renal/liver function, stroke, bleeding history, labile interna-
tional normalized ratio [INR], elderly >65 years, drug consumption/
alcohol abuse)24,25 scores for each patient. In the HAS-BLED score, 
the labile INR component of the score was not included because this 
information was not available for the entire study population. Both 
algorithms have been shown to predict thromboembolism and bleed-
ing accurately.23,25
Information on the quality of in-hospital care reflected whether the 
patient had received a range of recommended processes of care, in-
cluding early admission to a specialized stroke unit, early administra-
tion of antiplatelet or anticoagulant therapy, early examination with 
computed tomography or MRI, early assessment by a physiotherapist 
and an occupational therapist, and early nutritional risk assessment.26 
We computed the percentage of relevant processes of care received 
for each patient as a measure of the quality of in-hospital stroke care.
INR measurements were available from all hospitals and general 
practices for patients from Central Region Denmark and the North 
Jutland Region (≈32% of the total Danish population). We retrieved 
data on INR measurements on the day of stroke admission.
Statistical Analysis
We first examined the association between the patient-related char-
acteristics and the preadmission use of OAT within the entire study 
population to identify patient-related predictors of OAT use. The as-
sociation was examined using multivariable logistic regression with 
mutual adjustment of the covariates.
We used multiple imputation to impute the missing values 
among the covariates assuming that data were missing at ran-
dom (Stata command: ice).27 We created 5 data sets on the basis 
Figure. Patient flow diagram. OAT indicates oral anticoagulation 
treatment.






170  Stroke  January 2014
(Continued)
Table 1. Characteristics of Patients With Acute Stroke With Atrial Fibrillation According to Preadmission OAT Use
Characteristics
All Patients Propensity Score–Matched Patients
OAT User (n=2492) Non–OAT User (n=8864) OAT User (n=2175) Non–OAT User (n=2175)
Age, mean (SD) 77.0 (9.0) 79.5 (9.9) 77.2 (9.0) 77.6 (9.8)
Age, distribution, n (%)
  <65 y 330 (13.2) 1036 (11.7) 283 (13.0) 319 (14.7)
  65–74 y 508 (20.4) 1267 (14.3) 423 (19.5) 403 (18.5)
  ≥75 y 1654 (66.4) 6561 (74.0) 1469 (67.5) 1453 (66.8)
Sex, n (%)
  Men 1381 (55.4) 3759 (42.1) 1155 (53.1) 1140 (52.4)
CHA2DS2-VASc
  Median (10%–90% percentile) 5 (3–7) 5 (3–7) 5 (3–7) 5 (3–7)
  n (%)
   0 12 (0.5) 26 (0.3) 6 (0.3) 9 (0.4)
   1 21 (0.8) 43 (0.5) 14 (0.9) 15 (0.7)
   ≥2 2459 (98.7) 8795 (99.2) 2155 (99.1) 2151 (98.9)
HAS-BLED
  Median (10%–90% percentile) 2 (3–5) 2 (3–5) 2 (3–5) 2 (3–5)
  n (%)
   0–3 1437 (57.7) 5224 (58.9) 1257 (57.8) 1168 (53.7)
   ≥4 1055 (42.3) 3640 (41.1) 918 (42.2) 1007 (46.3)
Comorbidity, n (%)
  Congestive heart failure 556 (22.3) 1446 (16.3) 462 (21.2) 465 (21.4)
  Hypertension 1370 (55.0) 3513 (39.6) 1164 (53.5) 1138 (52.3)
  Previous stroke or TIA or 
thromboembolism
873 (35.0) 2289 (25.8) 760 (35.2) 559 (25.9)
  Vascular disease history 566 (22.7) 1862 (21.0) 487 (22.4) 524 (24.1)
  Diabetes mellitus 364 (14.6) 1002 (11.3) 311 (14.3) 309 (14.2)
Charlson Comorbidity index, n (%)
  No comorbidity, 0 431 (17.3) 2010 (22.7) 389 (17.9) 406 (18.7)
  Moderate comorbidity, 1–2 1250 (50.2) 4337 (48.9) 1089 (50.1) 1037 (47.7)
  Severe comorbidity, ≥3 811 (32.5) 2517 (28.4) 697 (32.1) 732 (33.7)
Type of stroke, n (%)
  Ischemic 1985 (79.7) 8316 (93.8) 1836 (84.4) 1856 (85.3)
  Intracerebral hemorrhage 507 (20.4) 548 (6.2) 339 (15.6) 319 (14.7)
Previous admission with atrial 
fibrillation, n (%)
2109 (84.6) 4570 (51.6) 1793 (82.4)  1823 (83.8)
Education, n (%)
  Long 252 (10.1) 761 (8.6) 214 (9.8) 210 (9.7)
  Medium 694 (27.9) 1721 (19.4) 576 (26.5) 567 (26.1)
  Short 1118 (44.9) 3465 (39.1) 970 (44.6) 988 (45.4)
  Missing 428 (17.2) 2917 (32.9) 415 (19.1) 410 (18.9)
Employment, n (%)
  Used 165 (6.6) 554 (6.3) 144 (6.6) 140 (6.4)
  Unemployed 17 (0.7) 33 (0.4) 14 (0.6) 12 (0.6)
  Pensioner (age) 2203 (88.4) 7945 (89.6) 1925 (88.5) 1927 (88.6)
  Pensioner (disability) 103 (4.1) 275 (3.1) 88 (4.1) 91 (4.2)
  Missing 4 (0.2) 57 (0.6) 4 (0.2) 5 (0.2)
Income, n (%)
  High 904 (36.3) 2860 (32.3) 761 (35.0) 777 (35.7)
  Medium 766 (30.7) 2998 (33.8) 678 (31.2) 667 (30.7)






Johnsen et al  OAT and Stroke Outcome   171
of aforementioned covariates. The outcome measures were aver-
aged across the 5 imputations correcting for between- and within- 
imputation variation.
Second, we examined the association between the preadmis-
sion OAT use and the clinical outcomes. In these analyses, we used 
propensity score matching (5-1 digit matching, Greedy method) to 
Table 1. Continued
Characteristics
All Patients Propensity Score–Matched Patients
OAT User (n=2492) Non–OAT User (n=8864) OAT User (n=2175) Non–OAT User (n=2175)
  Low 816 (32.7) 2948 (33.3) 732 (33.7) 726 (33.4)
  Missing 6 (0.2) 58 (0.7) 4 (0.2) 5 (0.2)
Antihypertensive drug, n (%) 2140 (85.9) 6180 (69.7) 1846 (84.9) 1757 (80.8)
  Thiazides, n (%) 458 (18.4) 1432 (16.2) 392 (18.0) 391 (18.0)
  Loop diuretics, n (%) 862 (34.6) 2369 (26.7) 728 (33.5) 729 (33.5)
  Potassium-sparing diuretics, n (%) 212 (8.5) 452 (5.1) 173 (8.0) 171 (7.9)
  ACE inhibitors/AT-II antagonists, 
n (%)
1032 (41.4) 2467 (27.8) 853 (39.2) 837 (38.5)
  β-Blockers, n (%) 1188 (47.7) 2975 (33.6) 998 (45.9) 995 (45.8)
  Calcium antagonists, n (%) 675 (27.1) 1772 (20.0) 583 (26.8) 576 (26.5)
Lipid-lowering drugs, n (%) 587 (23.6) 1171 (13.2) 454 (20.9) 453 (20.8)
Platelet inhibitors, n (%) 641 (25.7) 3985 (45.0) 612 (28.1) 606 (27.9)
  Acetylsalicylic acid 603 (24.2) 3629 (40.9) 576 (26.5) 548 (25.2)
  Clopidogrel 45 (1.8) 297 (2.3) 41 (1.9) 47 (2.2)
  Dipyridamole+acetylsalicylic acid 37 (1.5) 651 (7.3) 37 (1.7) 97 (4.5)
Antidiabetic drugs, n (%) 323 (13.0) 873 (9.9) 275 (12.6) 266 (12.2)
Thrombolysis, n (%) 15 (0.6) 173 (2.0) 15 (0.7) 19 (0.9)
BMI, n (%)
  <18.5 59 (2.4) 350 (4.0) 57 (2.6) 69 (3.2)
  18.5–<25 665 (26.7) 2630 (29.7) 588 (27.0) 557 (25.6)
  ≥25 769 (30.9) 2420 (27.3) 667 (30.7) 673 (30.9)
  Missing 999 (40.1) 3464 (39.1) 863 (39.7) 876 (40.2)
Drinks/wk, n (%)
  >14 for women/>21 for men 107 (4.3) 381 (4.3) 95 (4.4) 98 (4.5)
  ≤14 for women/≤21 for men 1875 (75.2) 6439 (72.6) 1630 (74.9) 1630 (74.9)
  Missing 510 (20.5) 2044 (23.1) 450 (20.7) 447 (20.6)
Smoking habits, n (%)
  Never 775 (31.1) 2882 (32.5) 687 (31.6) 717 (33.0)
  Daily 415 (16.7) 1635 (18.5) 370 (17.0) 354 (16.3)
  Occasionally 28 (1.1) 99 (1.1) 23 (1.1) 24 (1.1)
  Former (>½ y) 647 (26.0) 1826 (20.6) 546 (25.1) 512 (23.5)
  Missing 627 (25.2) 2422 (27.3) 549 (25.2) 568 (26.1)
Recommended processes of early 
stroke care received, %, median 
(10%–90% percentiles)
71.4 (25.0–100.0) 66.7 (20.0–100.0) 71.4 (25.0–100.0) 71.4 (20.0–100.0)
Year of admission, n (%)
  2003 232 (9.3) 1102 (12.4) 214 (9.8) 218 (10.0)
  2004 322 (12.9) 1473 (16.6) 301 (13.8) 319 (14.7)
  2005 371 (14.9) 1391 (15.7) 330 (15.2) 342 (15.7)
  2006 368 (14.8) 1235 (13.9) 324 (14.9) 310 (14.3)
  2007 404 (16.2) 1244 (14.0) 341 (15.7) 340 (15.6)
  2008 391 (15.7) 1120 (12.6) 325 (14.9) 309 (14.2)
  2009 404 (16.2) 1299 (14.7) 340 (15.6) 337 (15.5)




-VASc, congestive heart failure, hypertension, age≥75 years, 
diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65–74 years, sex category; age≥75 years and previous stroke carry doubled risk weight; 
HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history, labile international normalized ratio (INR), elderly >65 years, drug consumption/alcohol abuse; 
OAT, oral anticoagulant treatment; and TIA, transient ischemic attack.
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reduce the risk of bias attributable to confounding because preadmis-
sion OAT use was not randomly assigned in the study population.28,29 
We aimed to match each OAT user with 1 nonuser with similar pro-
pensity score using replacement. The propensity score was based on 
the covariates listed in Table 1 (except for quality of early stroke care). 
We did not stratify by other covariates when matching. The variables 
included in the propensity score model were selected among avail-
able baseline variables on the basis of known associations with use of 
OAT and the studied outcomes. As recommended, the model was not 
specified according to statistical criteria.30 An absolute standardized 
difference <10% and a variance ratio between 0.8 and 1.25 were con-
sidered to support the assumption of balance between the groups30,31 
(Figures I and II in the online-only Data Supplement, ○ for the entire 
study population [n=11 356] and ●  for the propensity score–matched 
patients [n=4350]).
The matching was followed by conditional logistic (stroke sever-
ity and 30-day mortality rate) or Cox proportional hazards regres-
sion stratified on the matched pairs (length of stay) analysis. In the 
analyses on 30-day mortality rate and length of stay, we adjusted 
for differences in the quality of early stroke care. We repeated the 
analyses while stratifying for type of stroke (ischemic stroke versus 
ICH). Furthermore, the analyses on 30-day mortality rate were re-
peated while also adjusting for stroke severity (Scandinavian Stroke 
Scale score) to evaluate stroke severity as a mediator. Finally, we 
examined the role of the intensity of preadmission OAT as reflected 
by the INR value (measured on the date of admission with stroke). 
These analyses were restricted to patients residing in Central Region 
Denmark or the North Jutland Region, where data on INR values 
were available (564 OAT users and 564 propensity score–matched 
with non–OAT users).
All data analyses were performed using SAS version 9.2 (SAS 
Institute) and Stata version 11.0 (StataCorp). Figures were generated 
using R (x64 version 2.12.1).
Results
Table 1 displays patient characteristics of the entire study 
population (n=11 356) and the propensity score–matched 
Table 2. Crude and Mutually Adjusted OR With 95% CI of 
Preadmission OAT Use Among Patients With Acute Stroke With 
Atrial Fibrillation
Characteristics Crude OR (95% CI) Adjusted OR (95% CI)
CHA2DS2-VASc
  0 1.00 1.00
  1 1.28 (0.92–1.78) 1.39 (0.99–1.94)
  ≥2 1.46 (1.10–1.94) 1.96 (1.43–2.67)
   Congestive heart failure 1.56 (1.38–1.75) 1.52 (1.33–1.73)
   Hypertension 1.86 (1.70–2.03) 2.06 (1.86–2.27)
   Age
    <65 y 1.00 1.00
    ≥65–74 y 1.54 (1.37–1.72) 1.20 (0.98–1.47)
    ≥75 y 0.69 (0.63–0.76) 0.88 (0.72–1.08)
   Diabetes mellitus 1.34 (1.18–1.53) 1.17 (1.02–1.35)
   Stroke/TIA/thromboembolism 1.55 (1.41–1.70) 1.71 (1.54–1.89)
   Vascular disease 1.16 (1.03–1.31) 1.05 (0.92–1.20)
   Men 1.69 (1.54–1.85) 1.62 (1.46–1.80)
HAS-BLED
  0–3 1.00 1.00
  ≥4 1.17 (1.04–1.32) 1.12 (0.99–1.27)
   Renal disease 1.26 (1.05–1.51) 0.97 (0.80–1.19)
   Liver disease 1.00 (0.67–1.50) 0.92 (0.59–1.42)
   Previous major bleeding or 
predisposition to bleeding
1.25 (1.10–1.43) 1.08 (0.93–1.26)
   Platelet inhibitors 0.41 (0.37–0.45) 0.34 (0.31–0.38)
   NSAIDs 0.84 (0.75- 0.95) 0.85 (0.75–0.97)
   Alcohol usage history 0.77 (0.59–1.00) 0.59 (0.44–0.79)
Dementia 0.50 (0.40–0.62) 0.51 (0.40–0.63)
Chronic pulmonary disease 1.30 (1.14–1.48) 1.27 (1.11–1.45)
Connective tissue disease 1.17 (0.96–1.43) 1.12 (0.91–1.37)
Any tumor 1.03 (0.90–1.18) 1.01 (0.88–1.17)
Leukemia 2.38 (1.21–4.69) 2.30 (1.15–4.58)
Lymphoma 1.24 (0.70–2.19) 1.04 (0.58–1.86)
Metastatic solid tumor 0.77 (0.50–1.21) 0.74 (0.47–1.17)
Education
  Long 1.00 1.00
  Medium 1.22 (1.02–1.45) 1.23 (1.02–1.47)
  Short 0.88 (0.76–1.01) 0.90 (0.77–1.06)
Employment
  Used 1.00 1.00
  Unemployed 1.72 (0.93–3.17) 2.14 (1.15–4.00)
  Pensioner (age) 0.95 (0.79–1.13) 0.90 (0.73–1.11)
  Pensioner (disability) 1.13 (0.86–1.49) 1.16 (0.87–1.55)
Income
  High 1.00 1.00
  Medium 0.81 (0.73–0.90) 0.84 (0.74–0.84)
  Low 0.88 (0.79–0.98) 0.98 (0.87–1.11)
BMI
  <18.5 1.00 1.00
  18.5–<25 1.45 (1.16–1.81) 1.43 (1.13–1.80)
Table 2. Continued
Characteristics Crude OR (95% CI) Adjusted OR (95% CI)
  ≥25 1.83 (1.46–2.30) 1.77 (1.41–2.23)
Smoking habits
  Never 1.02 (0.91–1.16) 1.03 (0.91–1.17)
  Daily 1.00 1.00
  Occasionally 1.07 (0.61–1.90) 1.09 (0.62–1.92)
  Former (>½ y) 1.35 (1.17–1.57) 1.27 (1.09–1.48)
Year of admission
  2003 1.00 1.00
  2004 1.04 (0.86–1.25) 1.04 (0.86–1.25)
  2005 1.27 (1.06–1.52) 1.29 (1.07–1.55)
  2006 1.42 (1.18–1.70) 1.42 (1.18–1.71)
  2007 1.54 (1.29–1.85) 1.54 (1.28–1.86)
  2008 1.66 (1.38–1.99) 1.62 (1.35–1.96)
  2009 1.48 (1.23–1.77) 1.47 (1.22–1.76)




-VASc, congestive heart failure, 
hypertension, age≥75 years, diabetes mellitus, previous stroke/transient 
ischemic attack, vascular disease, age 65–74 years, sex category; age≥75 years 
and previous stroke carry doubled risk weight; CI, confidence interval; HAS-
BLED, hypertension, abnormal renal/liver function, stroke, bleeding history, labile 
international normalized ratio (INR), elderly >65 years, drug consumption/alcohol 
abuse; NSAIDs, nonsteroidal anti-inflammatory drugs; OAT, oral anticoagulant 
treatment; OR, odds ratio; and TIA, transient ischemic attack.
(Continued)
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patients (n=4350). A total of 2492 of 11 356 patients 
(21.9%) used OAT at the time of admission with stroke. 
When restricting the study population to patients with a 
previous admission with AF, 2109 of 6679 patients (31.6%) 
used OAT at the time of admission. The median time from 
admission with AF to admission with stroke was 573 days 
(25%/75% percentiles, 147/1471) among these patients.
Predictors of Preadmission OAT Use
Table 2 presents the crude and mutually adjusted associa-
tion between a range of patient-related characteristics and 
preadmission use of OAT in the entire study population 
(n=11 356). Higher CHA2DS2-VASc score at the time of 
admission was associated with a higher chance of pread-
mission OAT use, whereas no overall association was found 
between HAS-BLED score and preadmission OAT use. 
Furthermore, we observed an increase in OAT use with cal-
endar time.
No substantial differences were seen restricting the analy-
ses to patients with a previous admission with AF (data not 
shown).
Preadmission OAT Use and Clinical Outcomes
The comparisons of the clinical outcomes were made among 
the propensity score–matched patients (n=4350). We were 
able to identify a suitable non–OAT users for 2175 of 2492 
OAT users (87.3%). The imbalances in the covariates were 
largely removed by the propensity score matching (Figures I 
and II in the online-only Data Supplement).
Preadmission OAT users had a lower overall risk of severe 
stroke at the time of admission when compared with non–
OAT users (Table 3). The lower risk was restricted to patients 
with ischemic stroke, whereas no difference in severity was 
observed among patients with ICH. When restricting to the 
OAT users with available data on admission INR and the cor-
responding propensity score–matched nonusers, we found the 
lowest odds ratios of severe stroke among OAT users with an 
INR value between ≥2.00 and 3.00 or >3.00 when compared 
with non–OAT users.
Median length of stay was 7 days (25%–75% percentiles; 
3–17) among the preadmission OAT users versus 8 days 
(25%–75% percentiles, 4–18) among the non–OAT users, 
corresponding to a marginally increased propensity score–
matched adjusted hazard ratio of discharge of 1.06 (95% con-
fidence interval, 1.00–1.14).
Overall 30-day mortality rate was also lower among OAT 
users (Table 4). The lower overall mortality was driven by 
a low mortality among OAT users admitted with ischemic 
stroke, whereas OAT users with ICH had an increased mortal-
ity when compared with non–OAT users with ICH. We found 
no differences in 30-day mortality rate between preadmission 
OAT users and non–OAT users when also adjusted for stroke 
severity (propensity score–matched adjusted odds ratio, 1.06; 
95% confidence interval, 0.81–1.38). When restricting to 
patients with available INR data, we found indications of a 
lower mortality among OAT users with an INR value on the 
day of admission <3.00 although the risk estimates did not 
reach statistical significance.
Discussion
Only 1 of 5 patients with AF used OAT at the time of admis-
sion with stroke in this nationwide study although the patients 
in general were characterized by a high predicted thrombo-
embolic risk. Even among patients who had previously been 
admitted to hospital with AF, <1 of 3 patients with AF used 
OAT. In propensity score–matched analyses, preadmission 
use of OAT was associated with lower stroke severity, lower 
30-day mortality rate, and marginally shorter length of stay.
The low use of OAT in our study population is compara-
ble with previous reports on patients with AF admitted with 
stroke7–13 and patients with AF in general.14 Improvements 
over time have been observed, as is also the case in our study, 
across geographical settings and healthcare systems, which 
may reflect the effect of national and international promotion 
of guidelines recommendations; however, still a high propor-
tion of eligible patients with AF remains insufficiently treated, 
in particular, when the intensity of the OAT is also taken into 
account.
The underuse of OAT is particularly troublesome when 
considering the findings on the association between OAT and 
clinical outcome after stroke among patients with AF found 
in our study and in previous studies. Our findings among 
patients with ischemic stroke are in line with several smaller 
existing studies, which have also reported preadmission OAT 
to be associated with lower ischemic stroke severity7,10–13 and 
lower mortality risk, in particular, among patients with an 
INR>2.00.7,11,12 We also found that the lower mortality among 
OAT users seemed to be mediated by the lower stroke severity, 
which is in accordance with previous findings.11
Table 3. Propensity Score–Matched Association Between 
Preadmission Use of OAT and Risk of Severe Stroke 






  No OAT (ref.) 647/1848 (35.0) 1.00
  OAT 540/1905 (28.3) 0.74 (0.63–0.86)
Type of stroke
  Ischemic stroke
   No OAT (ref.) 506/1581 (32.0) 1.00
   OAT 383/1602 (23.9) 0.67 (0.56–0.81)
  Intracerebral 
hemorrhage
   No OAT (ref.) 141/267 (52.8) 1.00
   OAT 157/303 (51.8) 1.20 (0.66–2.17)
Intensity of OAT
  No OAT (ref.) 224/566 (39.5) 1.00
  INR <2.00 78/215 (36.4) 0.88 (0.61–1.26)
  INR ≥2.00–3.00 57/224 (25.5) 0.52 (0.37–0.75)
  INR >3.00 35/128 (27.4) 0.58 (0.37–0.90)
Overall and subgroup analysis according to preadmission intensity of oral 
anticoagulation treatment (OAT). CI indicates confidence interval; and OR, odds 
ratio.
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A key challenge in the process of implementing OAT 
among patients with AF, which have lasted since the 1990s, 
is the concerns about bleeding risk.14 These concerns are 
related to inadequate assessment of stroke risk, includ-
ing both thromboembolic and bleeding related, in patients 
with AF. The risk of inducing a fatal or severe ICH on the 
basis of OAT is a particular concern in this context. The 
outcome of patients with ICH receiving OAT is, therefore, 
of major importance when examining the overall effect of 
OAT on stroke outcomes on a population level. However, to 
date, only the study by Audebert et al11 seems to have tried 
to account for the potentially adverse prognostic effect of 
preadmission OAT on patients with ICH (patients with ICH 
were also included in the study by Haeusler et al13 but seem 
not to have been included in the analyses on clinical out-
come). Audebert et al11 included 86 patients with ICH in a 
study based on data from 2 academic and 12 community hos-
pitals in Germany participating in a nonrandomized, com-
munity intervention study. Therefore, our study is the first 
population-based, nationwide study examining the effect 
of preadmission OAT use on hospitalized stroke outcomes, 
including both ischemic stroke and ICH. The relevance of 
including patients with ICH when studying the effect of OAT 
is underlined by the fact that ≈1 of 5 strokes among patients 
with AF in our study was an ICH. However, although we 
found a higher mortality among hospitalized patients with 
ICH using OAT at the time of admission, the increased risk 
did not offset the substantially lower mortality among the 
much higher number of patients with AF with ischemic 
stroke using preadmission OAT. In combination with the 
data from the existing studies, these findings clearly suggest 
that preadmission OAT have an overall beneficial effect on 
clinical outcome after stroke. It is noteworthy that no studies 
to date seem to have found preadmission OAT to be associ-
ated with a worse clinical outcome. It remains to be clari-
fied whether the possible beneficial effects of OAT are also 
found with use of the new generation of oral anticoagulants, 
including dabigatran, rivaroxaban, and apixaban.
The strengths of our study included the prospective, pop-
ulation-based, and propensity score–matched design with 
complete follow-up, limiting the risk of bias and confound-
ing. Furthermore, the total number of patients included in our 
study (n=11 356) was >3-fold higher than the total number of 
patients in all previous studies (n=3686).7–13 The large sample 
size was particularly evident with regards to patients with ICH 
(1055 patients included in our study versus 114 patients in all 
previous studies).
The validity of our estimates depends on the accuracy of the 
registries. Lack of information on nonhospitalized patients 
with stroke, including the patients who died before reaching 
the hospital, could at least theoretically introduce a selection 
bias if OAT users were more (or less) likely not to be hospi-
talized when compared with non–OAT users. However, only 
few patients with stroke die early after the start of symptoms, 
and there is a long tradition in Denmark for admitting almost 
all patients with acute stroke to hospital.32 The patients with 
AF included in our study population either had a known his-
tory of AF or were diagnosed with AF on admission with the 
stroke. We could not differentiate completely between these 
2 groups. However, this limitation seemed to be of minor 
importance because we also found a low rate of OAT use 
when restricting the population to patients with a previous 
AF admission.
Although we used a well-balanced propensity score–
matched design, we cannot exclude the possibility that our 
results remain influenced by confounding factors because of 
the observational nature of the study design. Furthermore, 
we used filled prescriptions as a proxy measure for actual 
OAT use although it is likely that a proportion of the patients 
was not compliant with the treatment, or their INRs might 
not have been in good control because of other factors (eg, 
change dietary habits or use of new medications). Such mis-
classification of OAT use would lead to an underestimation 
of the true effect of preadmission OAT use on stroke out-
comes. Finally, we used stroke severity, length of hospital 
stay, and 30-day mortality rate as clinical outcomes. Other 
outcomes, in particular functional level after discharge (eg, 
modified Rankin score), are also of major interest; however, 
such data were not available in our study population.
In conclusion, only few patients with acute stroke with AF 
received OAT at the time of hospitalization with stroke. In a 
propensity score–matched analysis, preadmission OAT was 
associated with less severe stroke and lower 30-day mortality 
rate. Further efforts seem warranted to ensure OAT to all eli-
gible patients with AF because OAT seems to reduce the risk 
of cardioembolic stroke and at the same time the risk of an 
adverse clinical outcome should a stroke occur.
Table 4. Propensity Score–Matched Association Between 
Preadmission Use of OAT and 30-Day Mortality
Events/n (%)
Propensity Score–Matched 
Adjusted OR (95% CI)*
All patients
  No OAT (ref.) 433/2175 (19.9) 1.00
  OAT 382/2175 (17.6) 0.83 (0.71–0.98)
Type of stroke
  Ischemic stroke
   No OAT (ref.) 302/1856 (16.3) 1.00
   OAT 219/1836 (11.9) 0.73 (0.60–0.90)
  Intracerebral 
hemorrhage
   No OAT (ref.) 131/319 (41.1) 1.00
   OAT 163/339 (48.1) 1.99 (1.03–3.82)
Intensity of OAT
  No OAT (ref.) 126/566 (22.2) 1.00
  INR <2.00 35/215 (16.5) 0.69 (0.44–1.08)
  INR ≥2.00–3.00 39/224 (17.6) 0.75 (0.49–1.14)
  INR >3.00 28/128 (21.6) 0.96 (0.59–1.59)
CI indicates confidence interval; OAT, oral anticoagulation treatment; and OR, 
odds ratio.
*Adjusted for quality of in-hospital stroke care including early admission to 
a specialized stroke unit, early administration of antiplatelet or anticoagulant 
therapy, early examination with computed tomography or MRI, early assessment 
by a physiotherapist and an occupational therapist, and assessment of 
nutritional risk.






Johnsen et al  OAT and Stroke Outcome   175
Sources of Funding
The study was supported by a grant from Bristol-Myers Squibb 
(BMS) and Pfizer. BMS and Pfizer had no influence on the study 
design, data collection, the presentation of data, or the conclusions 
made.
Disclosures
Dr Johnsen is member of an advisory board for BMS/Pfizer and has re-
ceived speakers honoraria from Bayer, Boehringer-Ingelheim, BMS, 
Pfizer, and AstraZeneca. Dr Hansen is member of advisory boards 
for BMS/Pfizer and Boehringer-Ingelheim and has received speakers 
honoraria from Boehringer-Ingelheim, BMS/Pfizer, and AstraZeneca. 
Dr Husted is member of advisory boards for AstraZeneca, Bayer, and 
BMS/Pfizer and has received research grants from GSK, Boehringer-
Ingelheim, BMS, Pfizer, and GlaxoSmithKline. The other authors 
report no conflicts.
References
 1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. 
Prevalence, age distribution, and gender of patients with atrial 
fibrillation. Analysis and implications. Arch Intern Med. 1995;155: 
469–473.
 2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent 
risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
 3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contribu-
tor to stroke in the elderly. The Framingham Study. Arch Intern Med. 
1987;147:1561–1564.
 4. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute 
stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 
1996;27:1765–1769.
 5. Thygesen SK, Frost L, Eagle KA, Johnsen SP. Atrial fibrillation in 
patients with ischemic stroke: a population-based study. Clin Epidemiol. 
2009;1:55–65.
 6. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in 
patients with non-valvular atrial fibrillation and no previous history 
of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 
2005:CD001927.
 7. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. 
Effect of intensity of oral anticoagulation on stroke severity and mortal-
ity in atrial fibrillation. N Engl J Med. 2003;349:1019–1026.
 8. Indredavik B, Rohweder G, Lydersen S. Frequency and effect of optimal 
anticoagulation before onset of ischaemic stroke in patients with known 
atrial fibrillation. J Intern Med. 2005;258:133–144.
 9. Paciaroni M, Agnelli G, Caso V, Venti M, Alberti A, Milia P, et al. 
Prior use of antithrombotic agents and neurological functional out-
come at discharge in patients with ischemic stroke. J Thromb Haemost. 
2006;4:1957–1961.
 10. O’Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C, 
et al; Investigators of the Registry of the Canadian Stroke Network. 
Preadmission antithrombotic treatment and stroke severity in patients 
with atrial fibrillation and acute ischaemic stroke: an observational study. 
Lancet Neurol. 2006;5:749–754.
 11. Audebert HJ, Schenk B, Schenkel J, Heuschmann PU. Impact of pre-
stroke oral anticoagulation on severity and outcome of ischemic and 
hemorrhagic stroke in patients with atrial fibrillation. Cerebrovasc Dis. 
2010;29:476–483.
 12. Schwammenthal Y, Bornstein N, Schwammenthal E, Schwartz R, 
Goldbourt U, Tsabari R, et al. Relation of effective anticoagulation 
in patients with atrial fibrillation to stroke severity and survival. Am J 
Cardiol. 2010;105:411–416.
 13. Haeusler KG, Konieczny M, Endres M, Villringer A, Heuschmann PU. 
Impact of anticoagulation before stroke on stroke severity and long-term 
survival. Int J Stroke. 2012;7:544–550.
 14. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of 
oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 
2010;123:638–645.e4.
 15. Mainz J, Krog BR, Bjørnshave B, Bartels P. Nationwide continuous qual-
ity improvement using clinical indicators: the Danish National Indicator 
Project. Int J Qual Health Care. 2004;16(suppl 1):i45–i50.
 16. Lindenstrøm L, Boysen G, Christiansen LW, á Rogvi-Hansen B, Nielsen 
PW. Reliability of Scandinavian Neurological Stroke Scale. Cerebrovasc 
Dis. 1991;1:103–107.
 17. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in 
ischemic stroke--background and study protocol. Stroke. 1985;16:885–890.
 18. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil 
Registration System. A cohort of eight million persons. Dan Med Bull. 
2006;53:441–449.
 19. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient 
Register. Scand J Public Health. 2011;39(7 suppl):30–33.
 20. Langagergaard V, Palnum KH, Mehnert F, Ingeman A, Krogh BR, 
Bartels P, et al. Socioeconomic differences in quality of care and clini-
cal outcome after stroke: a nationwide population-based study. Stroke. 
2011;42:2896–2902.
 21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of 
classifying prognostic comorbidity in longitudinal studies: development 
and validation. J Chronic Dis. 1987;40:373–383.
 22. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical 
risk stratification for predicting stroke and thromboembolism in atrial 
fibrillation using a novel risk factor-based approach: the euro heart sur-
vey on atrial fibrillation. Chest. 2010;137:263–272.
 23. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen 
J, et al. Validation of risk stratification schemes for predicting stroke and 
thromboembolism in patients with atrial fibrillation: nationwide cohort 
study. BMJ. 2011;342:d124.
 24. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A 
novel user-friendly score (HAS-BLED) to assess 1-year risk of major 
bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 
2010;138:1093–1100.
 25. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson 
C, et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: com-
parison of two established bleeding prediction schemes in a nationwide 
cohort. J Thromb Haemost. 2011;9:1460–1467.
 26. Ingeman A, Pedersen L, Hundborg HH, Petersen P, Zielke S, Mainz J, 
et al. Quality of care and mortality among patients with stroke: a nation-
wide follow-up study. Med Care. 2008;46:63–69.
 27. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et 
al. Multiple imputation for missing data in epidemiological and clinical 
research: potential and pitfalls. BMJ. 2009;338:b2393.
 28. Rubin DB. Estimating causal effects from large data sets using propen-
sity scores. Ann Intern Med. 1997;127(8 pt 2):757–763.
 29. Rubin DB. The design versus the analysis of observational studies for 
causal effects: parallels with the design of randomized trials. Stat Med. 
2007;26:20–36.
 30. Austin PC. Propensity-score matching in the cardiovascular surgery 
literature from 2004 to 2006: a systematic review and suggestions for 
improvement. J Thorac Cardiovasc Surg. 2007;134:1128–1135.
 31. Austin PC. An Introduction to Propensity Score Methods for Reducing 
the Effects of Confounding in Observational Studies. Multivariate Behav 
Res. 2011;46:399–424.
 32. Thorvaldsen P, Davidsen M, Brønnum-Hansen H, Schroll M. Stable 
stroke occurrence despite incidence reduction in an aging population: 
stroke trends in the danish monitoring trends and determinants in cardio-
vascular disease (MONICA) population. Stroke. 1999;30:2529–2534.






Mehnert and Steen Elkjær Husted
Søren Paaske Johnsen, Marie Louise Svendsen, Morten Lock Hansen, Axel Brandes, Frank
Hospitalized With Acute Stroke and Atrial Fibrillation: A Nationwide Study
Preadmission Oral Anticoagulant Treatment and Clinical Outcome Among Patients
Print ISSN: 0039-2499. Online ISSN: 1524-4628 
Copyright © 2013 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Stroke 
doi: 10.1161/STROKEAHA.113.001792
2014;45:168-175; originally published online November 26, 2013;Stroke. 
 http://stroke.ahajournals.org/content/45/1/168
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://stroke.ahajournals.org/content/suppl/2013/11/26/STROKEAHA.113.001792.DC1
Data Supplement (unedited) at:
  
 http://stroke.ahajournals.org//subscriptions/
is online at: Stroke  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer process is available in the
Request Permissions in the middle column of the Web page under Services. Further information about this
Once the online version of the published article for which permission is being requested is located, click 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office.Strokein
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:






SUPPLEMENTARY MATERIAL  
 
Figure I: Standardized differences in variables included in the propensity score for the entire 
study population (light dots) and for the propensity score-matched patients (black dots). 
 
 
Figure II: Variance ratios of variables included in the propensity score for the entire study 
population (light dots) and for the propensity score-matched patients (black dots). 
 
